Badheeb Ahmed M, Al Sedran Mohammed K, Ahmed Faisal, Al Sidran Ibrahim K, Al Qurayshah Mohammed H, Abu Bakar Abdullah, Obied Hamoud Y, Seada Islam A, Aman Abdelaziz, Badheeb Mohamed
Oncology, King Khalid Hospital, Oncology Center, Najran, SAU.
Emergency Medicine, King Khalid University Hospital, Najran, SAU.
Cureus. 2024 Jan 20;16(1):e52608. doi: 10.7759/cureus.52608. eCollection 2024 Jan.
Background Hepatocellular carcinoma (HCC) represents the most common primary liver malignancy, with a high fatality rate. Relatively, Saudi Arabia has a high incidence of HCC, which is detected in later stages with a poor prognosis. This study aims to investigate the patterns, outcomes, and mortality predictors of HCC in Saudi Arabia. Method A retrospective study from April 2018 to June 2022 included patients with HCC who were diagnosed and managed at the Najran Oncology Center, Saudi Arabia. Through our cancer registry, the patients' clinical, laboratory, radiological, and survival profiles were extracted and analyzed to assess factors associated with mortality using a univariate analysis. The overall survival was calculated by the Kaplan-Meier method. Results The study involved 52 patients with an average age of 74.6 years, predominantly male (the male-to-female ratio is 2.25:1). Viral infections were the primary cause of liver disease in 40.3% (n=21) of patients. At diagnosis, the Child-Pugh class distribution included 23.1% (n=12) patients in class A, 36.5% (n=19) patients in class B, and 40.4% (n=21) patients in class C. Uninodular tumors with ≤50% liver extension were observed in 65.4% (n=34) of cases, and 30.8% (n=16) had portal vein thrombosis. Elevated alpha-fetoprotein (AFP) levels were noted in 48.1% (n=25) of patients, with 23.1% (n=12) exceeding 400 ng/mL. Curative resection was performed in 32.7% (n=17) of patients. The mean survival time was 23±11.8 months (median of 22.5 months, minimum of six, and maximum of 49 months). Relapse occurred in seven (13.5%) cases, while new metastasis occurred in 20 (38.5%) cases. During the study period, 26 (50.0%) patients died. The main cause of death was disease progression in 15 (28.8%) patients. Univariate analysis showed that AFP>400 ng/mL (OR: 4.68; 95% CI: 1.87-11.66, p=0.001), presence of relapse (OR: 0.16; 95% CI: 0.03-0.78, p=0.023), abdominal ascites (OR: 3.38; 95% CI: 1.25-9.14, p=0.016), advanced the Cancer of the Liver Italian Program (CLIP) score (OR: 0.60; 95% CI: 0.41-0.88, p=0.009) were associated with higher mortality rate and were statistically significant. Conclusion Most cases of HCC in our patients were attributed to viral hepatitis, with the majority having liver cirrhosis. Higher AFP (>400 ng/mL), relapse, abdominal ascites, and a higher cancer CLIP score were associated with poorer outcomes. Targeted screening and health education should be advocated; in addition, social determinants should be proactively addressed.
肝细胞癌(HCC)是最常见的原发性肝脏恶性肿瘤,病死率高。相对而言,沙特阿拉伯的HCC发病率较高,且多在疾病晚期才被发现,预后较差。本研究旨在调查沙特阿拉伯HCC的发病模式、治疗结果及死亡预测因素。
一项回顾性研究,纳入了2018年4月至2022年6月期间在沙特阿拉伯纳季兰肿瘤中心诊断和治疗的HCC患者。通过癌症登记系统,提取并分析患者的临床、实验室、影像学及生存资料,采用单因素分析评估与死亡相关的因素。采用Kaplan-Meier法计算总生存期。
该研究共纳入52例患者,平均年龄74.6岁,男性居多(男女比例为2.25:1)。40.3%(n=21)的患者肝病主要病因是病毒感染。诊断时,Child-Pugh分级分布为:A级23.1%(n=12),B级36.5%(n=19),C级40.4%(n=21)。65.4%(n=34)的病例为单结节肿瘤,肝延伸≤50%,30.8%(n=16)有门静脉血栓形成。48.1%(n=25)的患者甲胎蛋白(AFP)水平升高,其中23.1%(n=12)超过400 ng/mL。32.7%(n=17)的患者接受了根治性切除术。平均生存时间为23±11.8个月(中位数为22.5个月,最短6个月,最长49个月)。7例(13.5%)出现复发,20例(38.5%)出现新的转移。研究期间,26例(50.0%)患者死亡。主要死亡原因是疾病进展,共15例(28.8%)。单因素分析显示,AFP>400 ng/mL(OR:4.68;95%CI:1.87-11.66,p=0.001)、存在复发(OR:0.16;95%CI:0.03-0.78,p=0.023)、腹水(OR:3.38;95%CI:1.25-9.14,p=0.016)、晚期意大利肝脏肿瘤计划(CLIP)评分(OR:0.60;95%CI:0.41-0.88,p=0.009)与较高的死亡率相关,且具有统计学意义。
我们研究中的大多数HCC病例归因于病毒性肝炎,大多数患者伴有肝硬化。较高的AFP(>400 ng/mL)、复发、腹水和较高的癌症CLIP评分与较差的治疗结果相关。应提倡有针对性的筛查和健康教育;此外,还应积极解决社会决定因素。